Yildirim, H. C. Et Al. 2024. The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer. Medicine (United States) , vol.103, no.30 .

Yildirim, H. C., Buyukkor, M., KAVGACI, G., Celik, B. Ş., Yucel, K. B., Dursun, B., ... Chalabiyev, E.(2024). The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer. Medicine (United States) , vol.103, no.30.

Yildirim, Hasan Et Al. "The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer," Medicine (United States) , vol.103, no.30, 2024

Yildirim, Hasan C. Et Al. "The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer." Medicine (United States) , vol.103, no.30, 2024

Yildirim, H. C. Et Al. (2024) . "The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer." Medicine (United States) , vol.103, no.30.

@article{article, author={Hasan Cagri Yildirim Et Al. }, title={The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer}, journal={Medicine (United States)}, year=2024}